Javascript must be enabled to continue!
The effect of aspirin on colorectal cancer incidence in African Americans.
View through CrossRef
4085 Background: From 2011 to 2016, the incidence and mortality rate of colorectal cancer(CRC) were highest among African Americans(AA), compared to other US racial/ethnic groups. Long-term aspirin use is recommended as a strategy to reduce the risk of CRC. Yet, there is scant information on the chemopreventive effect of aspirin among AA. It is imperative to assess whether the reported chemo-preventive effect also occurs in AA. Our central hypothesis is that aspirin use in AA is associated with a lower incidence of CRC, irrespective of race/ethnicity. Methods: We conducted a secondary analysis, using data from AA participants in the Atherosclerosis Risk in Communities(ARIC) longitudinal study, who did not have CRC at enrollment, from 1987 to 1998. We extracted demographic, clinical and mortality data to compare the incidence of CRC among participants taking aspirin compared to those who were not taking aspirin, stratified by age, tobacco use, and body mass index. All-cause mortality and CRC mortality will also be assessed, and we will use Cox proportional hazard regression to determine the relationship between aspirin use and CRC incidence, and mortality. Results: At baseline in 1987, 15,026 participants enrolled in the ARIC study, 25% of whom were AA, median age 54(range 44-66), including 46.7% who reported using aspirin. We analyzed follow-up data from 10,960 participants in 1996-1998, 20% of whom were AA, and 56.9% of whom were taking aspirin. Non-AA participants were more likely to report using aspirin at baseline and follow-up, compared to AA, 53% vs 30% and 59% vs 50% respectively. After 10years, the total incidence of CRC in AA participants was 1% compared with 1.1% in non-AA(p = 0.7). There was no difference in CRC incidence by aspirin use among all participants, and when stratified by race(among all participants p = 0.81, amongAA p = 0.68, among non-AA p = 0.94). Conclusions: We found no difference in the incidence of CRC among AA compared to Caucasians, by aspirin use. Investigation of consistency and/or dose of aspirin use by race may provide further insights on the relationship between aspirin use and CRC incidence, comparing AA to Caucasians.
American Society of Clinical Oncology (ASCO)
Title: The effect of aspirin on colorectal cancer incidence in African Americans.
Description:
4085 Background: From 2011 to 2016, the incidence and mortality rate of colorectal cancer(CRC) were highest among African Americans(AA), compared to other US racial/ethnic groups.
Long-term aspirin use is recommended as a strategy to reduce the risk of CRC.
Yet, there is scant information on the chemopreventive effect of aspirin among AA.
It is imperative to assess whether the reported chemo-preventive effect also occurs in AA.
Our central hypothesis is that aspirin use in AA is associated with a lower incidence of CRC, irrespective of race/ethnicity.
Methods: We conducted a secondary analysis, using data from AA participants in the Atherosclerosis Risk in Communities(ARIC) longitudinal study, who did not have CRC at enrollment, from 1987 to 1998.
We extracted demographic, clinical and mortality data to compare the incidence of CRC among participants taking aspirin compared to those who were not taking aspirin, stratified by age, tobacco use, and body mass index.
All-cause mortality and CRC mortality will also be assessed, and we will use Cox proportional hazard regression to determine the relationship between aspirin use and CRC incidence, and mortality.
Results: At baseline in 1987, 15,026 participants enrolled in the ARIC study, 25% of whom were AA, median age 54(range 44-66), including 46.
7% who reported using aspirin.
We analyzed follow-up data from 10,960 participants in 1996-1998, 20% of whom were AA, and 56.
9% of whom were taking aspirin.
Non-AA participants were more likely to report using aspirin at baseline and follow-up, compared to AA, 53% vs 30% and 59% vs 50% respectively.
After 10years, the total incidence of CRC in AA participants was 1% compared with 1.
1% in non-AA(p = 0.
7).
There was no difference in CRC incidence by aspirin use among all participants, and when stratified by race(among all participants p = 0.
81, amongAA p = 0.
68, among non-AA p = 0.
94).
Conclusions: We found no difference in the incidence of CRC among AA compared to Caucasians, by aspirin use.
Investigation of consistency and/or dose of aspirin use by race may provide further insights on the relationship between aspirin use and CRC incidence, comparing AA to Caucasians.
Related Results
Abstract 5758: Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
Abstract 5758: Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
Abstract
Compelling epidemiologic data, supported by experimental evidence, suggest aspirin may improve survival in breast cancer patients. However, recent clinical ...
Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year population cohort study in Hong Kong
Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year population cohort study in Hong Kong
Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, has been found to possess protective effects against cancer development in the Western populat...
Abstract 793: NOSH-aspirin and 5-fluorouracil demonstrate synergistic efficacy in a xenograft model of colon cancer
Abstract 793: NOSH-aspirin and 5-fluorouracil demonstrate synergistic efficacy in a xenograft model of colon cancer
Abstract
Introduction: Work in cancer biology, epidemiology and preclinical models has made it clear that non-steroidal anti-inflammatory drugs (NSAIDs) in general a...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity
Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity
Objective: To evaluate and provide management strategies for patients with aspirin or nonselective nonsteroidal antiinflammatory drug (NSAID) sensitivity. Data Sources: Literature ...
Abstract A99: Early colorectal cancer in an inner city hospital: Is the current guideline detecting preneoplastic lesions early enough?
Abstract A99: Early colorectal cancer in an inner city hospital: Is the current guideline detecting preneoplastic lesions early enough?
Abstract
Background: Early colorectal cancer refers to cancer diagnosed prior to the screening age of 50 years old or before the age of 55. Each patient's risk for t...
ROLE OF ASPIRIN AS PROPHYLAXIS AGAINST COLORECTAL CANCER
ROLE OF ASPIRIN AS PROPHYLAXIS AGAINST COLORECTAL CANCER
Introduction: Colorectal cancer (Bowel Cancer) is cancer of colon and rectum that are the parts of large intestine. [1] Symptoms are pain on defecation, blood and mucus in feces.[2...
Abstract 3681: Aspirin acetylates glucose 6 phosphate dehydrogenase and inhibits its activity in colon cancer cells.
Abstract 3681: Aspirin acetylates glucose 6 phosphate dehydrogenase and inhibits its activity in colon cancer cells.
Abstract
Epidemiological studies have demonstrated a significant correlation between regular aspirin use and reduced colon cancer incidence and mortality. Although a...

